Tempest Therapeutics News

HC Wainwright & Co. : The Tempest Therapeutics (TPST.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $47.00.

HC Wainwright & Co. : The Tempest Therapeutics (TPST.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $47.00.

Zhitong FinanceMay 11 03:02

Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)

TipRanksMay 10 20:12

Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical Advancements

TipRanksMay 10 18:25

Tempest Therapeutics Q1 2024 GAAP EPS $(0.36) Beats $(0.37) Estimate

Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.37) by 2.7 percent.

BenzingaMay 10 06:02

Tempest Therapeutics | 10-Q: Quarterly report

Futu NewsMay 10 04:35 · Announcements

Tempest Therapeutics 1Q Loss/Shr 36c >TPST

Tempest Therapeutics 1Q Loss/Shr 36c >TPST

Dow JonesMay 10 04:35

Press Release: Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update -- Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP

Dow JonesMay 10 04:29

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

PDF Version Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual M

Tempest TherapeuticsMay 9 12:00

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PDF Version BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune

Tempest TherapeuticsApr 26 12:00

Buy Recommendation for Tempest Therapeutics Backed by Promising Cancer Drug Developments

TipRanksApr 9 23:25

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

PDF Version BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune

Tempest TherapeuticsApr 9 12:00

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno

BenzingaApr 6 01:06

Tempest Announces Publication of Positive Data From Phase 1 Trial of TPST-1120 in Patients With Advanced Solid Tumors in Journal of Cancer Research Communications

PDF Version TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive r

Tempest TherapeuticsApr 4 12:00

Daily rights tracking | Tesla's deliveries fell far short of expectations! Large-cap buy order bets fell; Nikola options doubled, and the bearish ratio soared to 80%

Nvidia's overnight options traded 1.03 million, down 40% from the average daily volume, and slightly down to 57% from the bullish ratio. Calls due on Friday, with an exercise price of 900 US dollars, had the highest trading volume, with nearly 52,000 orders and about 10,000 unclosed positions.

Futu NewsApr 3 17:13

Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles

TipRanksMar 21 14:01

Tempest Therapeutics (TPST) Receives a Buy From Scotiabank

TipRanksMar 20 19:16

HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:TPST) with a Buy and maintains $47 price target.

BenzingaMar 20 18:39

Tempest FY23 EPS $(1.91) Vs $(3.09) YoY; Ended The Year With $39.2M In Cash And Cash Equivalents

Financial ResultsYear End 2023Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. The increase was primarily due to proceeds from t

BenzingaMar 20 04:40

Tempest Therapeutics GAAP EPS of -$1.91 Beats by $0.03

Seeking AlphaMar 20 04:37

Press Release: Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Reports Year End 2023 Financial Results and Provides Business Update -- Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across

Dow JonesMar 20 04:25